Lipocine Inc expected to post a loss of 43 cents a share - Earnings Preview

Lipocine

31/07/2026 13:49

Lipocine Inc LPCN.OQ LPCN.O is expected to  show a fall in quarterly revenue when it reports  results on August 3 (estimated) for the period ending June 30 2026
The Salt Lake City Utah-based  company is expected to report a 74.9% decrease in revenue to $156.5 thousand from $623 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Lipocine Inc is for a loss of 43 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Lipocine Inc is $6.00, about 184.4% above its last closing price of $2.11
This summary was machine generated July 31 at 12:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)